

Uptake of monoclonal antibody and anti-viral COVID-19 treatments in Scotland

How many people?

21 Dec
2021



26 Sept
2022

28,660



people with COVID-19 at high-risk of poor outcomes

14,464



with severe symptoms treated with these drugs



Some people may not have needed treatment to recover

Which treatments ?



Paxlovid
SARS-CoV-2 antiviral



Sotrovimab
Monoclonal antibody treatment



Molnupiravir
SARS-CoV-2 antiviral



Combination treatment



Who was least likely to be treated?


Of the 50.5% who received treatment, uptake is proportionately lowest among people:

Living in deprived areas  **30.1%**

Living with Stage 3+ Chronic Kidney Disease  **27.3%**

Aged 90+  **23.0%**

Sub-optimally vaccinated  **23.0%**

Living with Rheumatoid Arthritis or lupus (SLE)  **22.5%**

Living with HIV / AIDS  **21.9%**

Under 18  **20.3%**

Read more at: <https://edin.ac/3Bc6fJm>

98.5%

treated outpatients treated within 5 days of diagnosis

Only around half of eligible people received treatment, but the vast majority of those that did, were treated within the recommended timeframe.

